All News
ACR Award Recipients 2017
The American College of Rheumatology opened the 2017 meeting by inducting the new president (Dr. David Daikh) and officers and announcing its 2017 Award Winners. These recognitions are given annually to members who exhibit outstanding contributions to the field of rheumatology.
Read ArticleACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis
The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read ArticleJ&J Hit with a $247 Million Verdict over Metal-on-Metal Hip Replacements
Reuters reports that a federal jury has ordered Johnson & Johnson and its DePuy Orthopaedics division to pay $247 million settlment to six patients who suffered from its defective Pinnacle, metal-on-metal, hip implants. in the US. J&J says it will appeal this decision.
Read ArticleThe RheumNow Week in Review - 17 November 2017
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).
Read ArticleStroke Increased in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, inflammatory disease with systemic effects beyond the joints. While RA patients are known to have signficantly higher risks for cardiovascular disease and venous thromboembolic events, an association with stroke (CVA) is unclear.
Read ArticleDEA Cracks Down on Illicit Fentanyl
Reuters reports that U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.
Read ArticleGood News from ACR17 - Gout
The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read ArticleThiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk
JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents. (Citation source
Read ArticleMTX Doubles Hepatotoxicity Risk in Psoriasis Patients
A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when
Read ArticlePodcast of ACR17 - Day 4
Care to learn what you missed at last weeks ACR 2017 meeting in San Diego? Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers. Another good way to learn from RheumNow.
Read ArticleThe ACR17 RheumNow Week in Review - 10 November 2017
This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr.
Read ArticlePodcast of ACR 17 - Day 3
Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !
Read ArticleSeveral Agents Score on Radiographic Progression in Psoriatic Arthritis
Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.
Read ArticleACR 2017 - Day 3 and 4 Highlights
Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report). Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.
Read ArticleMy ACR Takeaways
With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice.
Health Economics of SLE
A number of presentations over the past few days have addressed the health economics of SLE.
Read ArticlePractice Patterns of PJP Prophylaxis Among ID Physicians
While the incidence of pneumocystis pneumonia (PJP) is low is patients with rheumatologic diseases the mortality is quite high compared to PJP in patients with HIV and infection can be prevented with appropriate prophylaxis.
Read ArticleCardiovascular Events: Allopurinol vs. Febuxostat
In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.
Read ArticleEULAR/ACR SLE Classification Criteria Update
Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.
Read Article